Mikko Keränen
@MikkoKeranen
Followers
730
Following
1K
Media
16
Statuses
1K
Clinical hematologist, MD, PhD, Docent in CCC, Helsinki U Hospital and postdoc in @hruh_research, Univ. of Helsinki, Finland. #ALL, #aplasticanemia & #cart
Helsinki
Joined May 2010
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML https://t.co/8aWRsHdyyy
#AML #leusm
0
13
42
🔥 Hot off the press: In a new study, Cooperrider et al., show that lenalidomide drives expansion of high-risk TP53-mutant clones, which may predispose MM patients to secondary blood cancers like t-MDS and t-ALL. @CanerSaygin @bdermanmd @UChicagoHemOnc
https://t.co/7J53StWiOy
0
7
31
No They Don't
mRNA vaccines cause leukemia
768
4K
44K
🧬 Real-World CAR-T in RRMM: Cilta-cel vs Ide-cel 💥 🇩🇪 Nationwide registry of 343 RRMM pts (≥3 prior lines): 🆚 Cilta-cel (n=77) vs Ide-cel (n=266) ✅ Cilta-cel superior: •ORR: 94% vs 82% •CR: 61% vs 39% •10-mo PFS: 76% vs 47% •Better CR conversion, esp. in PR/SD pts ⚠️
ashpublications.org
Key PointsThis is, to our knowledge, the first nationwide study to validate trial outcomes in RRMM, showing superior outcomes with cilta-cel compared with
1
8
16
THL esittää vyöruusurokotteen lisäämistä rokotusohjelmaan elin- ja kantasolusiirtopotilaille sekä hematologista syöpää sairastaville. Lisäksi THL esittää ikäperusteisia vyöruusurokotuksia kaikille 75-vuotiaille, mikäli rokotetta saadaan hankittua kohtuulliseen hintaan #rokotukset
ts.fi
THL:n mukaan vyöruusurokotukset tulisi mahdollistaa myös kaikille 75-vuotiaille, mikäli hankintahintaa saadaan alhaisemmaksi.
26
13
204
https://t.co/CkLiKbFS6D Lukusuositus. Asiantuntijat: Lääkkeiden teho tutkittava satunnaistetuilla vertailevilla lääketutkimuksilla. Oikotiet voivat johtaa negatiiviseen lopputulokseen, kun tehoa ei ole ja kustannukset vievät resursseja muilta tehokkaammilta toimilta.
hs.fi
Huoli Suomen jäävän ilman lääkkeitä näyttää vähäiseltä, kun päätöksiä tarkastellaan objektiivisten arviointikriteerien valossa.
0
3
14
Killer road map for in vivo CAR T cell #immunotherapy 👇
🧬 The Next Decade of In-Vivo CAR-T (2025–2035) We’re entering a new era where cell therapies are made inside the body. No apheresis. No chemo. Just a shot or a drip, and your T cells get reprogrammed on site. Here’s the clearest roadmap for the next 10 years 👇🏼
3
7
38
Amid the buzz around treating high-risk smoldering myeloma, do we truly understand its natural history in the modern era? @ManniMD1 is answering this with the SPOTLIGHT trial-a decentralized prospective study on active surveillance with local labs & WB DW-MRI. Remote enrollment
1
9
28
🚀🚀🚀 Exciting opportunity! We are hiring a post-doc researcher to work on targeted therapies for T-cell ALL...if you are passionate about innovative treatments, apply now! Please spread the word 🥳🥳🥳 https://t.co/VfSwis2DTR
0
11
16
Important commentary highlighting the futility of routine MGUS testing in patients with osteoporosis! Especially with @iStopMM data showing no association, unnecessary testing leading to medicalizing of healthy patients needs to stop!
Just out @TheLancetHaem: Sara, @ManniMD1 and I ask: should we screen for plasma cell dyscrasias in people with osteopenia or osteoporosis? New data from @iStopMM challenges previous dogma Interested to hear your thoughts
1
2
11
Earlier this week, Michelle and I called our friend @KamalaHarris. We told her we think she’ll make a fantastic President of the United States, and that she has our full support. At this critical moment for our country, we’re going to do everything we can to make sure she wins in
36K
101K
838K
THL suhtautuu kriittisesti yksityisten palveluiden Kela-korvausten nostoon. Yksityisen palvelutuotannon resursseja pitäisi hyödyntää osana hyvinvointialueiden toimintaa. #sote #perusterveydenhuolto
thl.fi
9
28
153
Definitely read Dr Prasad’s 🧵 I will try to put in layman’s terms why this matters:
JUST OUT in @JAMAOnc We look at all Adjuvant & Neoadjuvant drugs approved by FDA in last 5 years 43% of the time trials DON'T SAY what control arm pts get at relapse 75% of the time it is SUBOPTIMAL This means OS is *UNRELIABLE* @Timothee_MD 🧵 https://t.co/tdl1UsIlLD
4
21
72
Did you know that somatic mutations are also common in T cells and they impact their function? Please read further details from our new paper in @ScienceAdvances Congratulations for excellent work @sofie_lundgren and whole team! @HelsinkiUniMed
https://t.co/3rpxZ8RiuY
3
5
17
Randomized trials are for yesterday ?? I agree that cancer patients need early access to drugs but at the same time , drugs with marginal benifits and more toxicities are of no use to cancer patients. In countries, where patients have to pay from there own pockets, financial
14
21
66
This was the best abstract at ASH 2022 (IMO). It is now fully published: https://t.co/9HyaigkB01 Take-home message: Don't routinely order SPEP/light chains in pts with auto-immune diseases, and share with paper with your rheumatology colleagues! Stellar work! @iStopMM
acpjournals.org
Background: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. In previous registry-based, retrospective studies, autoimmune...
The single MOST important study presented at #ASH22 that can impact SO many patients. Please don’t routinely order SPEP/light chains in patients with autoimmune diseases. Such an honor to take a picture with @ingigerdursv by her incredible poster @sykristinsson @iStopMM #mmsm
2
14
48
#Weekend_review 🧵 #IMresident #hemoncfellows 1/10 JAK2 unmutated or non-PV erythrocytosis or idiopathic erythrocytosis Not every polycythemia/erythrocytosis is polycythemia vera (PV)! JAK2 unmutated or non-PV erythrocytosis: hereditary and acquired. Up to 70% of cases,
1
30
83